Market Closed -
Nasdaq
16:00:00 2024-06-26 EDT
|
5-day change
|
1st Jan Change
|
0.3511
USD
|
-2.47%
|
|
-7.63%
|
+18.37%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
21.48
|
535.1
|
255
|
73.82
|
38.09
|
46.24
|
-
|
-
|
Enterprise Value (EV)
1 |
21.48
|
535.1
|
255
|
76.18
|
38.09
|
19.04
|
0.7361
|
15.94
|
P/E ratio
|
-80.6
x
|
-27.8
x
|
-25.6
x
|
-2.17
x
|
-0.63
x
|
-1.13
x
|
-1.36
x
|
-1.82
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
2,598
x
|
353
x
|
156
x
|
58.2
x
|
137
x
|
8.5
x
|
1.18
x
|
EV / Revenue
|
-
|
2,598
x
|
353
x
|
161
x
|
58.2
x
|
56.6
x
|
0.14
x
|
0.41
x
|
EV / EBITDA
|
-
|
-
|
-
|
-1.61
x
|
-0.98
x
|
-0.43
x
|
-0.01
x
|
-0.49
x
|
EV / FCF
|
-
|
-
|
-
|
-1.72
x
|
-
|
-0.46
x
|
-0.01
x
|
-1.05
x
|
FCF Yield
|
-
|
-
|
-
|
-58%
|
-
|
-216%
|
-7,716%
|
-95.4%
|
Price to Book
|
-
|
-
|
-
|
20
x
|
-
|
1.5
x
|
1.57
x
|
1.8
x
|
Nbr of stocks (in thousands)
|
2,049
|
59,393
|
62,204
|
73,820
|
128,416
|
128,434
|
-
|
-
|
Reference price
2 |
10.48
|
9.010
|
4.100
|
1.000
|
0.2966
|
0.3600
|
0.3600
|
0.3600
|
Announcement Date
|
20-09-10
|
21-03-29
|
22-03-11
|
23-03-13
|
24-03-13
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
0.206
|
0.723
|
0.473
|
0.654
|
0.3365
|
5.44
|
39.31
|
EBITDA
1 |
-
|
-
|
-
|
-47.39
|
-38.84
|
-44.7
|
-58.95
|
-32.65
|
EBIT
1 |
-16.33
|
-20.21
|
-49.98
|
-48.41
|
-40.54
|
-40.05
|
-47.86
|
-36.38
|
Operating Margin
|
-
|
-9,812.62%
|
-6,912.59%
|
-10,234.46%
|
-6,198.78%
|
-11,902.08%
|
-879.78%
|
-92.54%
|
Earnings before Tax (EBT)
1 |
-
|
-18.87
|
-10.17
|
-29.92
|
-49.5
|
-43.8
|
-48.18
|
-35.62
|
Net income
1 |
-
|
-19.28
|
-9.74
|
-29.92
|
-49.5
|
-43.8
|
-48.18
|
-35.62
|
Net margin
|
-
|
-9,357.77%
|
-1,347.16%
|
-6,325.16%
|
-7,569.42%
|
-13,015.53%
|
-885.67%
|
-90.62%
|
EPS
2 |
-0.1300
|
-0.3238
|
-0.1600
|
-0.4600
|
-0.4700
|
-0.3200
|
-0.2640
|
-0.1975
|
Free Cash Flow
1 |
-
|
-
|
-
|
-44.19
|
-
|
-41.1
|
-56.8
|
-15.2
|
FCF margin
|
-
|
-
|
-
|
-9,342.49%
|
-
|
-12,213.97%
|
-1,044.12%
|
-38.67%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-09-10
|
21-03-29
|
22-03-11
|
23-03-13
|
24-03-13
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.199
|
0.03
|
0.035
|
0.174
|
0.234
|
0.107
|
0.269
|
0.108
|
0.17
|
0.073
|
0.075
|
0.0775
|
0.13
|
0.1
|
0.1
|
EBITDA
1 |
-
|
-13.14
|
-13.31
|
-9.572
|
-11.37
|
-10.33
|
-9.894
|
-9.103
|
-9.508
|
-8.812
|
-10.5
|
-11.7
|
-13.3
|
-
|
-
|
EBIT
1 |
-14.06
|
-13.34
|
-13.6
|
-9.805
|
-11.67
|
-10.73
|
-10.34
|
-9.542
|
-9.93
|
-9.232
|
-9.75
|
-10.29
|
-10.8
|
-9.9
|
-9.9
|
Operating Margin
|
-7,064.32%
|
-44,453.33%
|
-38,842.86%
|
-5,635.06%
|
-4,988.46%
|
-10,029.91%
|
-3,842.38%
|
-8,835.19%
|
-5,841.18%
|
-12,646.58%
|
-12,999.33%
|
-13,271.61%
|
-8,307.31%
|
-9,900%
|
-9,900%
|
Earnings before Tax (EBT)
1 |
4.208
|
-13.35
|
-4.534
|
-10.98
|
-1.054
|
-11.77
|
-25.14
|
-2.418
|
-10.17
|
-11.08
|
-10.34
|
-11
|
-11.36
|
-10
|
-10
|
Net income
1 |
4.423
|
-13.35
|
-4.534
|
-10.98
|
-1.054
|
-11.77
|
-25.14
|
-2.418
|
-10.17
|
-11.08
|
-10.34
|
-11
|
-11.36
|
-10
|
-10
|
Net margin
|
2,222.61%
|
-44,513.33%
|
-12,954.29%
|
-6,308.05%
|
-450.43%
|
-11,000%
|
-9,346.84%
|
-2,238.89%
|
-5,984.12%
|
-15,178.08%
|
-13,780.67%
|
-14,189.03%
|
-8,738.85%
|
-10,000%
|
-10,000%
|
EPS
2 |
0.0700
|
-0.2100
|
-0.0700
|
-0.1700
|
-
|
-0.1500
|
-0.2900
|
-0.0200
|
-0.0600
|
-0.0900
|
-0.0775
|
-0.0850
|
-0.0725
|
-0.0600
|
-0.0600
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22-03-11
|
22-05-09
|
22-08-15
|
22-11-07
|
23-03-13
|
23-05-12
|
23-08-14
|
23-11-07
|
24-03-13
|
24-05-08
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
2.36
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
27.2
|
45.5
|
30.3
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-0.0497
x
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-44.2
|
-
|
-41.1
|
-56.8
|
-15.2
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-378%
|
-
|
-143%
|
-136%
|
-31.6%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
0.0500
|
-
|
0.2400
|
0.2300
|
0.2000
|
Cash Flow per Share
2 |
-
|
-
|
-0.6000
|
-
|
-0.2400
|
-0.2200
|
-0.0500
|
Capex
1 |
0.39
|
1.33
|
5.18
|
-
|
1.5
|
2
|
2
|
Capex / Sales
|
187.86%
|
184.23%
|
1,094.93%
|
-
|
445.77%
|
36.76%
|
5.09%
|
Announcement Date
|
21-03-29
|
22-03-11
|
23-03-13
|
24-03-13
|
-
|
-
|
-
|
Last Close Price
0.36
USD Average target price
5
USD Spread / Average Target +1,288.89% Consensus |
1st Jan change
|
Capi.
|
---|
| +18.37% | 46.24M | | +16.49% | 122B | | +21.73% | 116B | | +22.18% | 27.03B | | -21.81% | 20.36B | | -16.89% | 16.43B | | -18.81% | 15.91B | | -44.74% | 15.6B | | +62.72% | 14.94B | | +3.09% | 13.59B |
Bio Therapeutic Drugs
|